Clinical Pipeline - B2 Receptor Antagonism
Deucrictibant is the only oral bradykinin B2-receptor antagonist currently in clinical development, to our knowledge.
Pharvaris is developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema.
On-Demand
Prophylaxis
Treatment Strategy
During the shared decision process, people living with HAE and their treating physicians, may opt to prevent attacks (prophylactic treatment) or may prefer to treat attacks (on-demand treatment) based on clinical assessment and personal choice.
By bringing the promise of both these new treatment options to people living with HAE, Pharvaris aims to enable those with HAE to have fewer disruptions in their daily activities, resulting in an improved quality of life.
Product Summary
Deucrictibant immediate-release (IR) capsule
- Rapid absorption12
Rapidly reaches therapeutic exposure within 15-30 minutes,13 making it optimal for on-demand oral treatment of AE-BK attacks.14
Deucrictibant extended-release (XR) tablet
- Sustained absorption9
Maintains sustained therapeutic exposure over 24 hours10 from day one, allowing for once-daily oral prevention of AE-BK attacks.11
Deucrictibant
Deucrictibant is the only oral B2 receptor antagonist currently in clinical development. We aim to develop distinct, optimized formulations for both the on-demand treatment, through rapid onset of activity, and prophylactic treatment, through prolonged therapeutic activity, of HAE.
